Sattva Neelapu

Deputy Department Chair Ad Interim, Department of Lymphoma/Myeloma, Division of Cancer Medicine · University of Pennsylvania Health System

Credentials: · · ·

History

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
New England Journal of Medicine · 2017 · First of 40 authors · 4,914 citations
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Review · Biology of Blood and Marrow Transplantation · 2019 · Last of 22 authors · Corresponding · 3,048 citations
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Case report · Nature Reviews Clinical Oncology · 2018 · First of 19 authors · 1,951 citations

[18F]4FN PET Imaging of Innate Immunity Activation During Immunotherapy-Induced Adverse Events
National Cancer Institute · R01
PI · $2.7M · University of Tx Md Anderson Can Ctr
2022–2027
Predictors of Clinical Outcome After Therapeutic Vaccination in Follicular Lympho
National Cancer Institute · R01
Contact PI · $1.7M · University of Tx Md Anderson Can Ctr
2011–2016
Enhancing Antitumor Immunity with Anti-PD-1 Antibody in Follicular Lymphoma.
National Cancer Institute · R21
Contact PI · $568.2K · University of Tx Md Anderson Can Ctr
2010–2011
Antigen Discovery and Development of Tumor-Specific Lymphoma Immunotherapy
National Cancer Institute · K23
Contact PI · $544.3K · University of Tx Md Anderson Can Ctr
2007–2011